Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation by Dan Tian et al.
RESEARCH ARTICLE Open Access
Quantitative analysis of insulin-like growth
factor 2 receptor and insulin-like growth
factor binding proteins to identify control
mechanisms for insulin-like growth factor 1
receptor phosphorylation
Dan Tian1, Isaiah Mitchell1 and Pamela K. Kreeger1,2*
Abstract
Background: The insulin-like growth factor (IGF) system impacts cellular development by regulating proliferation,
differentiation, and apoptosis, and is an attractive therapeutic target in cancer. The IGF system is complex, with two
ligands (IGF1, IGF2), two receptors (IGF1R, IGF2R), and at least six high affinity IGF-binding proteins (IGFBPs) that
regulate IGF ligand bioavailability. While the individual components of the IGF system are well studied, the question
of how these different components integrate as a system to regulate cell behavior is less clear.
Results: To analyze the relative importance of different mechanisms that control IGF network activity, we
developed a mass-action kinetic model incorporating cell surface binding, phosphorylation, and intracellular
trafficking events. The model was calibrated and validated using experimental data collected from OVCAR5, an
immortalized ovarian cancer cell line. We then performed model analysis to examine the ability of IGF2R or IGFBPs
to counteract phosphorylation of IGF1R, a critical step for IGF network activation. This analysis suggested that IGF2R
levels would need to be 320-fold greater than IGF1R in order to decrease pIGF1R by 25 %, while IGFBP levels would
need to be 390-fold greater. Analysis of The Cancer Genome Atlas (TCGA) data set suggested that this level of
overexpression is unlikely for IGF2R in ovarian, breast, and colon cancer. In contrast, IGFBPs can likely reach these
levels, suggesting that IGFBPs are the more critical regulator of IGF1R network activity. Levels of phosphorylated
IGF1R were insensitive to changes in parameters regulating the IGF2R arm of the network.
Conclusions: Using a mass-action kinetic model, we determined that IGF2R plays a minor role in regulating the
activity of IGF1R under a variety of conditions and that due to their high expression levels, IGFBPs are the dominant
mechanism to regulating IGF network activation.
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Background
The insulin-like growth factor (IGF) network plays im-
portant roles in homeostasis and disease by mediating
cell proliferation, differentiation, and apoptosis [1].
Elevated levels of IGF ligands have been observed in
ovarian, breast, and colon cancer, and are associated
with poor prognosis and resistance to treatment [2–6].
Therefore, the IGF network has been proposed as a
potential therapeutic target that could benefit a broad
group of patients. However, clinical trials with IGF-
targeted inhibitors have had mixed results [7]. While the
individual elements of the network have been well
characterized, it is less clear how these components
interact, information that may provide new methods to
better counteract IGF-mediated effects in cancer.
The IGF network is composed of two ligands (IGF1,
IGF2), two receptors (IGF1R, IGF2R), and a family of six
high affinity binding proteins (IGFBPs) [8]. IGF1 and
IGF2 are produced in the liver and other tissues, and act
both locally and following circulation through the blood-
stream to reach target tissues. Igf1−/− and Igf2−/− mice
were significantly smaller than their wildtype littermates,
displayed severe muscle dystrophy and died perinatally
[9, 10]. IGF1R is a receptor tyrosine kinase that binds
IGF1 and IGF2 to initiate a cascade of downstream sig-
naling pathways such as the MAPK/ERK and PI3K/
AKT. Similar to other receptor tyrosine kinases, IGF-
IGF1R complexes are internalized by receptor-mediated
endocytosis and degraded by the lysosome or recycled
back to the cell surface [11]. Igf1r−/− mice exhibited
severe growth restriction and died shortly after birth of
respiratory failure [12]. Additionally, IGF1R and the
closely related insulin receptor (IR) form signaling-
competent heterodimers of IGF1R/IR hybrid receptors
in cells that express both receptors [13]. IGF2R specific-
ally binds IGF2, but lacks an intracellular tyrosine kinase
domain [14]. While IGF2R cannot initiate downstream
signaling cascades, IGF2-IGF2R complexes undergo cel-
lular trafficking, potentially regulating extracellular IGF2
levels and providing an indirect mechanism to influence
cellular behavior [11]. Consistent with this, Igf2r−/−
mice exhibited increased levels of IGF2 and died
perinatally due to abnormal growth [15, 16]. In addition
to these interactions, circulating levels of IGF1 and IGF2
are regulated by high-affinity interactions with IGFBPs
[17]. These interactions increase ligand stability and
utilize some of the same residues as the ligand-receptor
interaction, leading to competitive inhibition [18].
The balance of these different IGF network components
(i.e., ligands, binding proteins, receptors) likely plays an
important role in maintaining healthy tissue. For example,
elevated IGF1 and IGF2 expression were linked to disease
progression and poor survival in ovarian cancer [2, 3].
Additionally, differences in receptor and binding protein
levels have been reported [19, 20], but in contrast to other
receptor systems, dramatic overexpression or mutations
that impact protein function appear to be rare [7]. There-
fore, it will be important to better understand how the
more subtle balances between these different components
influence network activity. In particular, IGFBPs and
IGF2R provide two separate mechanisms to regulate IGF2
bioavailability and have each been suggested as a potential
tumor suppressor [21–23]; however, it remains unclear
which plays the dominant role in regulating IGF2 activity
in tumors. Computational modeling is a useful method to
analyze how changes in individual components impact
network activity, and has been valuable in understanding
the impact of other signaling networks on tumor develop-
ment, progression, and treatment [24]. Most of the prior
models of the IGF network have focused exclusively on
IGF1R and have not incorporated the impact of IGF2R or
IGFBPs [25, 26]. We have previously developed a compu-
tational model of the interactions between IGF1, IGF1R,
and IGFBPs in ovarian cancer cells [27]. Analysis of this
model suggested, and experimental results confirmed, that
IGFBPs were key regulators of IGF1-mediated IGF1R
activation. In addition, a more complete model of the IGF
system in cartilage has been developed, incorporating
extracellular and cell surface interactions of IGF1, IGF2,
IGFBPs, IGF1R, and IGF2R [28]. Model analysis suggested
that IGF2R levels could influence IGF1R activation;
however, the impact of changes in the level of IGFBPs was
not examined and this analysis was not experimentally
validated. Therefore, to analyze the relative role of IGFBPs
and IGF2R in cancer, we developed a mass-action kinetics
model of the IGF network that incorporated IGF1, IGF2,
IGF1R, IGF2R, and IGFBPs. The model was calibrated
and validated using an ovarian cancer cell line, OVCAR5,
and then analyzed to determine the relative impact of
IGF2R and IGFBPs on IGF2-mediated IGF1R activation.
Results and discussion
A calibrated mass-action kinetic model accurately captures
pIGF1R dynamics
To examine which factors regulate IGF1R phosphoryl-
ation, and therefore IGF network activation, we devel-
oped a mass-action kinetic model that incorporated cell
surface interactions and intracellular trafficking events
following treatment with IGF1 and/or IGF2 (Fig. 1a).
Details about the model structure and parameters can
be found in Additional file 1. Where possible, parameter
values were obtained from literature or experimental
analysis of OVCAR5 cells (Additional file 2); remaining
parameters were fit to experimental timecourses of
phosphorylated IGF1R (pIGF1R) in OVCAR5 cells stim-
ulated with 1 nM IGF1, 10 nM IGF1, 1 nM IGF2, or 10
nM IGF2 (Fig. 1b, c).
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The experimental data demonstrated that after ligand
treatment, there was a rapid and transient peak in
pIGF1R (Fig. 1b, c). For treatment with high doses (10
nM IGF1 or IGF2), the level of pIGF1R remained above
50 % of the peak level at 30 min; in contrast, treatments
with lower doses (1 nM IGF1 or IGF2) did not result in
sustained activation. Additionally, IGF1 treatment was
observed to elicit a stronger peak in pIGF1R than IGF2
treatment for the same dose, consistent with previous
reports [29]. The experimental data was well-described
by the model solution, with the timing and magnitude of
the pIGF1R peak accurately captured, suggesting that
the model framework adequately described the dynamics
of the IGF system in response to either stimuli. We next
examined the model’s ability to predict the impact of
simultaneous exposure to IGF1 and IGF2, as cells in vivo
are frequently exposed to both stimuli. OVCAR5 were
treated with a mixture of 0.5 nM IGF1 and 0.5 nM IGF2
and pIGF1R was measured as a function of time. Experi-
mental results demonstrated that this mixture led to sig-
naling that was intermediate in magnitude relative to 1
nM of the individual ligands, suggesting that the system
behaves in a linear fashion when below saturating levels.
Comparison of model predictions and experimental data
demonstrated good agreement (Fig. 1d), validating the
model’s predictive capability.
Changes in IGF2R levels do not affect pIGF1R magnitude
or dynamics
IGF2R has been postulated to act as a tumor suppressor
by binding and clearing IGF2, thereby preventing activa-
tion of IGF1R [22]. To better understand the influence
of IGF2R on the IGF network, we utilized the model to
examine the effect of changes in IGF2R levels on IGF2-
induced phosphorylation of IGF1R. Simulations were
performed for conditions corresponding to 1 nM IGF2
and the level of IGF2R knockdown and overexpression
that was achieved experimentally in OVCAR5 (Fig. 2,
Additional file 3). To isolate the effects of IGF2R, simu-
lations were conducted assuming no IGFBPs were
present and experiments were performed in fresh
serum-free media to minimize cell-secreted IGFBPs [27].
Fig. 1 The IGF network model qualitatively and quantitatively captured pIGF1R experimental dynamics. a Diagram of molecular events included
in the model, double-sided arrows indicate reversible events. b, c Comparison of the best-fit model to experimental results for IGF1- (b) and
IGF2- (c) treated OVCAR5. d The calibrated model was used to predict the effect of a mixture of 0.5 nM IGF1 and 0.5 nM IGF2 on pIGF1R in
OVCAR5. In these experiments, IGF2 was added directly to the culture media, which contained OVCAR5-secreted IGFBPs. Model results are
represented by solid lines and experimental data are represented by circles or squares indicating average ± SD, n = 3
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While IGF2R sequestration of IGF2 is expected to regu-
late IGF1R activation [30], the validated model predicted
that IGF2R knockdown would have no discernable ef-
fect. The experimental results confirmed this prediction,
with no significant difference in pIGF1R at all time
points for either knockdown (Fig. 2a) or overexpression
(Fig. 2b). As our model only captured early time
dynamics, we tested the impact of knockdown and over-
expression of IGF2R on IGF2-induced proliferation and
determined that this change to the IGF network had no
significant long-term effects as well (Fig. 2c, d). In
contrast, prior studies in breast cancer cells showed that
decreased IGF2R expression resulted in a higher growth
rate [31] while increased IGF2R expression led to
decreased invasiveness and motility [32]. However, these
prior studies did not measure either the absolute level of
IGF receptors or the ratio of IGF2R to IGF1R, which
may significantly affect IGF network activation.
Therefore, we next utilized the model to determine
what ratio of IGF2R:IGF1R was needed for IGF2R to be
an effective suppressor of IGF2-mediated activation. The
model was utilized to simulate the effects of overex-
pressing IGF2R relative to IGF1R, with IGF2R:IGF1R
ranging from 1:1 to 100:1. As shown in Fig. 3a, an
IGF2R:IGF1R ratio of 100 would be necessary to reduce
the peak activation of IGF1R by 11.2 %. In the
experimental validation, IGF2R was overexpressed by
1.4-fold, resulting in an IGF2R:IGF1R ratio of approxi-
mately 1:1. As the IGF2R:IGF1R ratio needed for substan-
tial reduction in pIGF1R was dramatically higher than
what was achieved in OVCAR5, it was unsurprising that
the IGF2R overexpression had minimal impact experi-
mentally (Fig. 2). We next interrogated the TCGA data-
base for measurements of IGF receptor expression to
determine if this level of IGF2R overexpression is possible
in tumor samples. A complete compendium of protein ex-
pression of the different IGF system components is not
available through The Cancer Proteome Atlas (TCPA,
[33]); in particular, the reverse phase protein array used
for most samples in this database included IGFBP2 but
did not measure IGF1R or IGF2R. Therefore, we utilized
gene expression levels from RNA sequencing (RNA-Seq).
While transcription levels are not expected to correlate
precisely with protein levels, RNA-Seq data has been
shown to be qualitatively consistent with proteomic mea-
surements [34]. The TCGA database was utilized to com-
pare the relative expression of IGF2R to IGF1R in three
different carcinomas in which IGF activity has been re-
ported to play a role (ovarian serous cystadenocarcinoma
[35], breast invasive carcinoma [36], and colon adenocar-
cinoma [37]; Additional file 4). For all three tumor types,
IGF2R:IGF1R was generally less than 10, with only a few
Fig. 2 Alterations in IGF2R levels did not substantially impact phosphorylation of IGF1R or cell proliferation. a, b Model results predicted that
a complete knockdown (a) or a 1.4-fold overexpression (b) of IGF2R in OVCAR5 would not affect pIGF1R. This prediction was consistent with
experimental data collected from these conditions. In these experiments, IGF2 was added to fresh serum-free media, and therefore did not contain
OVCAR5-secreted IGFBPs. c, d IGF2-induced proliferation was not impacted by knockdown of IGF2R (c) nor a 1.4-fold overexpression of IGF2R
(d), p > 0.05
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tumors expressing as much as 25 times as much IGF2R.
Thus, while it is possible for the IGF2R:IGF1R ratio to
reach levels where the model would predict a substantial
suppression of pIGF1R, it is expected that this would be
rare in tumors. However, as a putative tumor suppressor,
it is possible that IGF2R levels are decreased during tumor
development, such that the ratio of the two receptors is al-
tered in the pathophysiological state. The level of IGF2R
was significantly lower in both breast and colon cancers
compared to normal tissue (p < 0.01, data for normal tis-
sue samples is not currently available in the TCGA data-
base for ovarian cancer), consistent with prior reports of
reduced IGF2R expression in hepatocellular carcinomas
compared to normal liver tissue [38]. However, IGF1R ex-
pression was also significantly lower for breast tumors (p <
0.01). Therefore, since both receptor levels may change
with tumor development, we also compared the
IGF2R:IGF1R ratio between tumor and normal tissue
(Additional file 4). Despite the decrease in IGF2R levels, this
ratio was unchanged for colon cancers and was actually sig-
nificantly higher for breast tumors relative to normal tissue,
even though the ratio did not reach levels that our model
predicts would impact signaling. Combined, the model
analysis, experimental results, and TCGA data suggest
that IGF2R does not play a substantial role in sup-
pressing IGF2 in the examined tumor types. This
does not preclude a role for IGF2R in other tumor
types; for example, hepatocellular carcinomas have
been found to have mutations in IGF2R [39].
Our previous study indicated that the extracellular
level of IGF1 relative to the available IGF1R level was an
important metric that impacted the activation of this
network [27]. Therefore, we hypothesized that a poten-
tial factor accounting for the inefficacy of IGF2R sup-
pression of IGF2 was the high amount of IGF2 relative
to IGF receptors in OVCAR5. The IGF2 treatment dose
of 1 nM was on the order of 10−9 nmol/cell while the
experimentally determined concentration of IGF2R was
on the order of 10−11 nmol/cell; therefore, even if every
IGF2R sequestered an IGF2 ligand there would still be a
substantial amount of IGF2 available to activate IGF1R.
To examine if the effectiveness of IGF2R in suppressing
pIGF1R was dependent on IGF2 dose, model analysis
was performed for a range of IGF2 doses to determine
the IGF2R:IGF1R ratio necessary to cut the peak pIGF1R
level by 50 % (Fig. 3b). This model analysis suggests that
for very low doses of IGF2, the amount of IGF2R that is
needed to impact the system does decrease; however,
even at doses as low as 0.01 nM IGF2, IGF2R would
need to be 188.8 times as abundant as IGF1R in order to
decrease pIGF1R activation to that extent. As physio-
logical concentrations of free IGF2 range from 0.2 to 2
nM [40, 41], this analysis provides further support that
IGF2R does not play a significant role in suppressing
IGF network activity in most tumors.
IGFBP levels impact levels of phosphorylated IGF1R
Our experimental results suggested that while IGF2R min-
imally impacted IGF1R network activity, the presence of
IGFBPs substantially impacted pIGF1R levels, with peak
activation increased by 3-fold when cell-secreted IGFBPs
were removed from the media (Fig. 1c vs. Fig. 2a,
replotted in Fig. 4a). Therefore, we next examined the role
of IGFBPs in regulating IGF2-induced network activity.
IGFBPs bind to circulating IGF1 or IGF2, sequestering the
ligand from proteases and controlling its presentation to
IGF1R [42]. While the regulatory role of IGFBPs in the
interaction between IGF ligands and their receptors is
well-known, there has been limited quantitative analysis of
the effect of this function. When simulations were run for
the baseline levels of IGF1R and IGF2R in OVCAR5,
pIGF1R was found to decrease with increasing levels of
IGFBP (Fig. 4b). Interestingly, IGFBPs were less effective
in controlling phosphorylation of IGF1R than IGF2R
when examined at the same ratio (Fig. 3a), since IGF2R
can target the ligand for degradation while IGFBPs only
Fig. 3 Model results suggest that IGF2R can suppress phosphorylation of IGF1R for specific quantitative combinations. a Model analysis demonstrated
that IGF2R would need to be 100 times more abundant than IGF1R in order to inhibit pIGF1R by 11.2 % in OVCAR5. b Increasing IGF2 treatment doses
increased the magnitude of IGF2R:IGF1R ratio required for 50 % inhibition of pIGF1R
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sequester it. As a result, IGFBP expression would still
need to be in large excess relative to IGF1R in order to
play a substantial role in IGF network activity. The initial
conditions for OVCAR5 indicate that for some tumor cell
lines this is possible, as the ratio of IGFBP to IGF1R per
cell was experimentally determined to be 543 (Additional
file 1). Therefore, we examined the TCGA data to com-
pare expression of IGFBP relative to IGF1R in ovarian,
breast, and colon carcinoma (Additional file 5). In contrast
to the moderate levels of IGF2R:IGF1R, the IGFBP:IGF1R
ratios for all three carcinomas were frequently between
100 and 200, indicating that IGFBPs might play a more
significant role than IGF2R in regulating the network
response to IGF2. Our prior results demonstrated that
IGFBP impacted IGF1-induced proliferation in OVCAR5
[27]; therefore, we examined if IGFBPs were sufficient to
counteract IGF2 in vitro. OVCAR5 were treated with
IGF2 in fresh serum-free media or in conditioned media
containing IGFBPs. Proliferation was significantly de-
creased in the presence of IGFBPs, further suggesting that
IGFBPs play a central role in regulating IGF network
response to IGF2 (Fig. 4c). To further confirm that this
inhibition resulted from IGFBPs and not another secreted
factor in the conditioned media, OVCAR5 were pretreated
with recombinant IGFPB3 prior to addition of IGF2, and a
similar effect was observed (Fig. 4d). This effect resulted
from both the high affinity of IGFBPs for IGF2 (Additional
file 1) and the production and secretion of large quantities
of IGFBPs relative to receptor levels. Importantly, IGFBP
levels have been shown to vary between healthy and
diseased states, providing a mechanism for IGF network
activity to change during disease development. For ex-
ample, IGFBP3 levels were inversely correlated with ovarian
cancer risk [43] and breast cancer patients had reduced
IGFBP-1, −3, and −6 serum levels compared to patients
with benign tumors [44].
Multivariate analysis further supports a limited role
for IGF2R
As the TCGA data clearly demonstrated that tumors sim-
ultaneously express IGF1R, IGF2R, and IGFBP, we next
examined the combined effect of IGF2R and IGFBP on
phosphorylation of IGF1R in response to IGF2. Model
simulations were run using combinations of IGF2R:IGF1R
and IGFBP:IGF1R that spanned the range identified in the
TCGA data set (0–10 for IGF2R, 0–500 for IGFBP). As
seen in Fig. 5, these two elements combine in an additive
fashion to regulate IGF1R activation. Therefore, while
IGF2R was able to supplement the ability of IGFBP to
Fig. 4 Model results suggest that IGFBP can suppress phosphorylation of IGF1R for specific quantitative combinations. a Treatment with IGF2 in
the presence of OVCAR5-secreted IGFBPs resulted in significantly lower levels of pIGF1R, data replotted from Figs. 1c and 2a. b Model results
demonstrated that IGFBP would suppress pIGF1R by 7 % when available at 100-fold the level of IGF1R. OVCAR5 levels of IGFBPs were 540-fold
the level of IGF1R, and were predicted to substantially decrease pIGF1R. c IGF2-induced proliferation was significantly decreased in the presence
of IGFBPs secreted by OVCAR5 cells. d IGF2-induced proliferation of OVCAR5 cells was significantly decreased in the presence of recombinant
IGFBP3, * indicates p < 0.05
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prevent IGF1R activation, the dominant control mechan-
ism at these levels is expected to remain extracellular lig-
and sequestration by IGFBPs.
It is possible that in other ovarian cancer cell lines or
tumors, a change in one of the rate parameters could
alter the network’s sensitivity to changes in the level of
IGF2R. To examine this possibility, a sensitivity analysis
was performed, examining first the effect of perturba-
tions to the individual parameters (Fig. 6a) and then the
effect of changes in the parameters in combination with
a 10-fold increase in IGF2R (Fig. 6b). The single-
parameter analysis indicated that the level of pIGF1R
was most sensitive to parameters that impacted the rate
of IGF1R phosphorylation/dephosphorylation (k7/k−7) or
IGF2-IGF1R association/dissociation (k5/k−5). This sensi-
tivity is not surprising, as those events are the most
proximal to the activation of IGF1R. The next most sen-
sitive parameters were k2 (IGF2-IGFBP association) and
k8 (internalization of unbound IGF1R). Interestingly, the
network was insensitive to all parameters regulating the
interaction of IGF2 and IGF2R, as well as IGF2R traffick-
ing. To determine if changes in these parameters impacted
sensitivity to the level of IGF2R, a multivariate analysis
was performed with a 10-fold increase in IGF2R in
combination with each rate. To prevent offsetting effects,
parameters were altered such that both perturbations
resulted in a decrease in the level of pIGF1R (Fig. 6b). The
ranking of the 10 most sensitive parameters did not
change from the initial analysis and the impact on pIGF1R
from a simultaneous change in parameters did not differ
substantially from the sum of the effects of changing each
rate and IGF2R individually. Combined, these analyses
suggest there is no synergy between the rate parameters
and sensitivity to IGF2R levels.
Conclusions
The model presented here constitutes an important
expansion of our foundational IGF model, which indi-
cated that IGFBPs played an essential role in regulating
IGF1-IGF1R interactions [27]. This expanded model in-
corporated the IGF2 axis of the IGF network (i.e., IGF2
and IGF2R) and was used to assess the hypothesized
roles of IGF2R and IGFBPs as tumor suppressors. Our
model suggested, and experimental results confirmed,
that IGF2R played only a minor role in counteracting
IGF2 treatment. To significantly impact network activa-
tion, model analysis further suggested that IGF2R would
need to be expressed at levels that are substantially
higher than IGF1R and which do not appear to be physio-
logically relevant in several tumor types. In contrast to our
analysis, a prior model of this system in cartilage
suggested the IGF2R might play a role in regulating IGF2
interactions with IGF1R [28]; however, these findings were
not confirmed experimentally and were not seen in our
model utilizing data from cancer cells.
The inability of IGF2R to impact IGF1R signaling
dynamics experimentally and under a variety of quanti-
tative scenarios raises the question of why the Igf2r−/−
mouse demonstrated a clear phenotype [15, 16] and
what role IGF2R actually plays in the cellular network. It
is of course possible that under conditions that were not
included in these simulations, IGF2R can impact the
IGF1R network. For example, despite IGFBP1 being the
dominant IGFBP in fetal development [45, 46], the levels
of IGF1BP in the fetal liver are only 4 % of the levels
found in the maternal decidua [47]. Given the low levels
of IGFBPs in fetal circulation, IGF2R could play a larger
role in regulating circulating levels of IGF2 than is seen
in the adult, explaining the effects seen in perinatal
Fig. 5 IGFBP and IGF2R demonstrated an additive effect when examined in combination. Model simulations of different combinations of IGF2R and
IGFBP levels indicated that increases in IGFBP and IGF2R would act together, but would not synergize, to counteract IGF2-induced phosphorylation
of IGF1R
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growth in the Igf2r−/− mouse. Additionally, the much
longer timescale of fetal development may amplify the
fairly modest effects seen in our simulations, resulting in
a more important role for IGF2R. Finally, it is important
to note that IGF2R has been shown to play a role in the
cellular network beyond the IGF axis, as mannose-6-
phosphate tagged proteins can also bind to IGF2R and
be trafficked to the lysosome [48].
Importantly, the combined effect of the multiple gen-
omic changes that lead to tumorigenesis could fundamen-
tally change the parameter space and resulting behavior of
the IGF network. For example, PTP1B, a phosphatase for
IGF1R [49], is expressed at significantly lower levels in
ovarian cancer cells compared to normal ovarian surface
epithelial cells [50]. While ovarian surface epithelia are no
longer considered to be the cell of origin for ovarian
cancer [51], changes in PTP1B levels in combination with
changes in the levels of other proteins could impact the
kinetics of IGF1R activation. Likewise, a recent study
demonstrated that clathrin-mediated, caveolae-mediated,
and clathrin-independent endocytosis were all lower in
non-small cell lung cancer cells compared to their normal
bronchial epithelial counterparts [52]. Further, the rates
for these processes also varied across a panel of non-small
cell lung cancer cell lines. This report, combined with our
finding that the IGF network was moderately sensitive to
internalization rates suggests that analysis of cellular
trafficking could prove useful to develop new therapeutic
approaches.
While the model suggested a limited role for IGF2R,
our analysis demonstrated that the high expression level
of IGFBPs makes them a key control mechanism in
response to IGF2 treatment, consistent with our prior
findings that IGFBPs regulated IGF1-mediated network
activation [27]. Additionally, due to their high expression
level, IGFBPs were able to interfere with IGF2 treatment
enough to slow cell proliferation. Our results demonstrate
the potential for models of the IGF network to examine
how system components interact to regulate behavior,
which may help to identify optimal ways to target the IGF
network for cancer therapy. In order to obtain a more
complete understanding of the IGF system in carcinogen-
esis, future model refinement should focus on the func-
tion of individual IGFBPs, which can elicit different
responses [17], and regulation of IGFBP-ligand inter-
actions by cell-secreted proteases [53].
Fig. 6 Sensitivity analysis demonstrated that pIGF1R was insensitive to changes in the IGF2R network. a Sensitivity of the integrated level of pIGF1R
when individual rate parameters were changed. A positive value indicates an increase in the level of pIGF1R. b Sensitivity of the integrated level of
pIGF1R when rate parameters are changed in combination with a 10-fold increase in the level of IGF2R. Parameters were altered such that both
perturbations resulted in a decrease in the level of pIGF1R
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Methods
Cell culture and reagents
OVCAR5 cells were originally isolated from a serous
ovarian carcinoma and were obtained from Dr. R. Bast
(MD Anderson Cancer Center, Houston, TX). As an
established member of the NCI-60 panel of cell lines, no
additional ethics approval was needed. Cells were main-
tained at 37 °C in a humidified 5 % CO2 atmosphere in a
complete culture medium composed of 1:1 (v/v) ratio of
MCDB 105 and Medium 199 (Corning, Manassas, VA)
supplemented with 10 % fetal bovine serum (Life
Technologies, Carlsbad, CA) and 1 % penicillin/strepto-
mycin. OVCAR5 cells were routinely tested and confirmed
to be mycoplasma negative using the MycoAlert® Myco-
plasma Detection Kit (Lonza, Rockland, ME). All reagents
were from Sigma-Aldrich (St. Louis, MO) or Thermo
Fisher Scientific (Waltham, MA) unless otherwise noted.
Measurement of phosphorylated IGF1R (pIGF1R)
OVCAR5 were plated in 10 cm plates at 5700 cells/cm2,
allowed to grow for 2 days, and then serum-starved for
24 h prior to treatment with recombinant human IGF1
or IGF2 (Peprotech, Rocky Hill, NJ). Cells were lysed at
times ranging from 0 to 30 min after treatment with
Bio-Plex lysis buffer (Bio-Rad Laboratories Inc.,
Hercules, CA). Total protein was measured by BCA
assay and the level of pIGF1R was determined by the
Bio-Plex pIGF1R (Tyr1131) assay on a Bio-Rad Bio-
Plex 100 Suspension Array system (Bio-Rad Labora-
tories Inc.).
siRNA knockdown of IGF1R and IGF2R
To knockdown IGF1R or IGF2R expression in OVCAR5,
cells were plated in 35 mm plates at 5300 cells/cm2,
allowed to attach for 6 h, and transfected for 24 h with
12.5 nM ON-TARGETplus Human IGF1R or IGF2R
SMARTpool siRNA using DharmaFECT 1 siRNA Trans-
fection Reagent (Dharmacon, Lafayette, CO). Transfected
cells were changed to fresh complete media for 24 h,
serum-starved for 24 h, and then treated with IGF ligands.
Non-targeting siRNA was used as a negative control.
Overexpression of IGF2R
pcDNA3.1(+)MPR-270, which expresses IGF2R under the
CMV promoter, was kindly provided by Dr. William S. Sly
(Saint Louis University, St. Louis, MO) [54]. OVCAR5
were plated in 35 mm plates at 5300 cells/cm2, allowed to
grow for 24 h, and transfected with 2.5 μg DNA per plate
using Lipofectamine® 3000 (Life Technologies) according
to the manufacturer’s instructions. Transfection efficiency
was determined to be 64 % by flow cytometry analysis of
transfection with pEGFP. After 6 h of transfection, the
media was changed to fresh complete media for 24 h, and
then the cells were serum-starved for 24 h prior to IGF
treatment. Transfection with pcDNA3.1(+) was used as a
negative control.
Quantification of cell proliferation
OVCAR5 were seeded in 12-well plates at 5300 cells/cm2,
allowed to grow for 2 days, and then serum-starved for
24 h (resulting in a final density of 126,000 cells/well).
IGF2 was then either spiked directly into conditioned
media (which contains cell-secreted IGFBPs, [27]) or
serum-free media was aspirated, cells were rinsed once
with PBS, and the IGF2 treatment was added with fresh
serum-free media. For experiments with IGFBP3, 15 nM
of recombinant human IGFBP3 (Peprotech) was added
30 min prior to treatment with IGF2. All experiments
were done with 1 mL of media per well. Cell proliferation
was quantified after 24 h of IGF2 treatment using the
Click-iT® EdU Alexa Fluor® 488 flow cytometry assay
(Life Technologies) according to manufacturer’s in-
structions. Cells were incubated with EdU for 6 h
prior to sample collection and analyzed on an Accuri
C6 flow cytometer (BD, Franklin Lakes, NJ). To in-
vestigate the effects of IGF2R knockdown and overex-
pression on IGF2-induced proliferation, transfected
cells were plated as described and treated with either
vehicle or 1 nM IGF2.
Mass-action kinetic model of IGF network
A mass-action kinetic model was developed to analyze
the surface binding interactions between IGF ligands
with IGFBPs, IGF1R, and IGF2R and the subsequent
intracellular trafficking events (Fig. 1a). There were a
total of 31 model parameters, of which 14 were deter-
mined experimentally or from published KD values for
IGF ligands with IGFBPs and IGF receptors (Additional
files 1 and 2). The remaining 17 adjustable fitting
parameters were determined by a least squares fit of the
numerical solution of Eqs. 1a-x (Additional file 1) to
experimental measurements of pIGF1R, using the
lsqcurvefit fitting routine and ode45 solver in MATLAB
v7.14 (MathWorks; Natick, MA). The lsqcurvefit routine
minimizes the sum of the squares of the residual error
between the model calculations and the experimental
data, and the ode45 solver uses a variable step Runge-
Kutta method. To ensure that the model found the
global minimum, model fits were performed using 1000
randomly chosen initial guesses for the fitted parame-
ters. For each of these combinations, the fitting routine
returned to the same minimum within the fitting routine
tolerance, suggesting this corresponds to a global mini-
mum. Model analysis focused on the level of pIGF1R as
IGF2-induced proliferation of OVCAR5 is dependent on
IGF1R kinase activity (Additional file 6, [27]).
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Analysis of data from The Cancer Genome Atlas (TCGA)
RNA sequencing (RNA-Seq) data for ovarian serous cysta-
denocarcinoma, breast invasive carcinoma, and colon
adenocarcinoma were obtained from TCGA (http://
cancergenome.nih.gov/). To compare the individual and
combined effectiveness of IGFBPs and IGF2R at inhibiting
pIGF1R, model calculations were performed over a range
of IGF2R:IGF1R and IGFBP:IGF1R ratios determined
from the ovarian cancer data (one to the mean + one SD).
This range encompasses greater than 80 % of the samples
in the TCGA database. RNA-Seq data for normal breast
and colon tissue were also obtained from the TCGA data-
base; however, normal ovarian tissue data was not available.
Sensitivity analysis
Sensitivity analysis was performed by increasing each
parameter value and determining the effect on the inte-
grated level of pIGF1R relative to the baseline condition.
To determine if changes in the parameter set would alter
the ability of IGF2R to regulate network activity, the
sensitivity for each parameter altered in combination
with a 10-fold increase in IGF2R was determined.
Statistical analysis
All data are represented as the mean ± standard deviation
and all experiments were performed with n = 3. Statistical
significance was evaluated using student’s t-test analysis,
with p < 0.05. All statistical calculations were performed
using the software package JMP 4.1 (SAS Institute,
Cary, NC).
Availability of data
All data is available in the additional files or through
the TCGA data portal https://tcga-data.nci.nih.gov/
tcga/tcgaHome2.jsp.
Additional files
Additional file 1: Detailed methods including the full set of
differential equations and assumptions used in the model,
experimental methods for determination of several rates and initial
conditions, experimental methods for validation of the IGF2R
knockdown and overexpression, and tables of both experimentally-
determined and model-fitted rates and initial conditions.
(DOCX 80 kb)
Additional file 2: Experimental results for the determination of
internalization rates for IGF1-IGF1R, IGF2-IGF1R, IGF2-IGF2R.
(PDF 162 kb)
Additional file 3: Experimental confirmation of IGF2R knockdown
and overexpression. (PDF 181 kb)
Additional file 4: Analysis of the TCGA data for IGF2R. (PDF 184 kb)
Additional file 5: Analysis of the TCGA data for IGFBPs. (PDF 197 kb)
Additional file 6: Experimental validation of the impact of IGF1R
and IR inhibition on IGF2-induced cell proliferation, demonstrating
that IGF2-induced proliferation was dependent on IGF1R kinase
activity and not IR kinase activity. (PDF 104 kb)
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